Clinical trial
Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6…
NCT00244621 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00244621 |
|---|---|
| Title | Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age |
| Official title | A Dose-ranging Safety and Pharmacokinetics Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 1 to Less That 6 Years of Age: A 4-week, Multicenter, Randomized, Double-blind Study With a 1-year, Open-label, Follow-up Period. |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | candesartan cilexetil (Atacand) |
| Enrollment | 95 |
| Start date | Nov 1, 2004 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Oct 27, 2005 |
| Last update posted | Aug 31, 2011 |
| Countries | Belgium, Denmark, France, Germany, Italy, Poland, Puerto Rico, Ukraine, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: